Across TCGA pan-cancer cohorts, C22orf46 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated C22orf46 data layer compared with 22 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher C22orf46 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C22orf46 expression acts as an unfavorable survival marker.
UCEC are the cancer types where C22orf46 Mutation most reproducibly stratifies survival.